Quasiketamines

Quasiketamines are a class of psychoactive compounds that share a structural resemblance to dissociative anesthetics like ketamine and phencyclidine. While not chemically identical, they are often grouped together due to their perceived effects and pharmacological mechanisms. These substances typically interact with the N-methyl-D-aspartate (NMDA) receptor in the brain, acting as antagonists. This interaction is thought to be responsible for their dissociative, anesthetic, and potentially hallucinogenic properties.

The term "quasiketaamine" itself is not a formal scientific classification but rather a colloquial descriptor used within recreational drug communities and by some researchers to categorize substances that exhibit ketamine-like effects without being direct ketamine analogs. Examples of compounds sometimes referred to as quasiketamines might include certain arylcyclohexylamines or other novel psychoactive substances (NPS) that modulate NMDA receptor activity.

Research into quasiketamines is limited, and their pharmacological profiles, safety, and long-term effects are largely unknown. Due to their classification as novel psychoactive substances, they are not subject to the same rigorous testing and regulation as approved pharmaceuticals. Their legal status can vary significantly by jurisdiction, often falling into gray areas or being explicitly banned as controlled substances. Individuals seeking information about these compounds are advised to consult scientific literature and reputable drug information resources, acknowledging the inherent risks associated with the use of unregulated substances.